IP Think Tank Cautions Against Breaking Gilead’s Truvada Patent

Drug Industry Daily
A A
As HIV patient advocates urge the federal government to “break” drug patents in an effort to lower the prices of HIV drugs, an intellectual property think tank cautioned that the tactic could backfire.

To View This Article:

Login

Subscribe To Drug Industry Daily